Beyond somatic mutations, germline polymorphisms in genes involved in drug metabolism and oxidative stress (e.g., carbonyl reductase, NAD(P)H oxidase, TOP2B) increase susceptibility to anthracycline-induced cardiotoxicity [135,136,137,138,139].Though still evolving, pharmacogenomics represents a promising avenue for risk stratification and the personalization of therapy in AL patients. The gene discussed is FMO5; the disease is axial length measurement.